Imipenem / Cilastatin / Relebactam (2) (Recarbrio®) – Bacterial infections, multiple indications


Start date 01.05.2022
Resolution 03.11.2022
INN Imipenem/Cilastatin/Relebactam
Brand name Recarbrio®
Pharm. company MSD Sharp & Dohme GmbH
G-BA procedure ID 2022-05-01-D-814
Therapeutic area Infectious diseases
Reason for procedure Initial assessment – Reserve antibiotic
Regulatory status Reserve antibiotic

G-BA resolution "Anwendungsgebiet des Beschlusses" (German)

Recarbrio is indicated for:

Treatment of hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) in adults.

Treatment of bacteremia for which there is or is suspected to be an association with HAP or VAP in adults.

Treatment of infections with aerobic Gram-negative pathogens in adults with limited treatment options.

Subpopulation Indication Comparator
a) Adults with hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP)
b) Adults with bacteraemia for which there is an association with HAP or VAP or suspected
c) Adults with infections due to aerobic gram-negative pathogens with limited treatment options

9. Associated procedures

<< List of all resolutions

Log in to read more ...

The AMNOG monitor is a subscription-based service for pharmaceutical manufacturers and institutions. Enter your account details here in order to analyse the results of the early benefit assessment in Germany – or contact us for more information.